Compare FBGL & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | XRTX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 3.9M |
| IPO Year | 2022 | 2018 |
| Metric | FBGL | XRTX |
|---|---|---|
| Price | $2.25 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.8K | ★ 346.0K |
| Earning Date | 11-23-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $392.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.35 |
| 52 Week High | $4.30 | $3.60 |
| Indicator | FBGL | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 28.81 |
| Support Level | $0.43 | $0.37 |
| Resistance Level | $4.30 | $2.26 |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | -0.21 | -0.07 |
| Stochastic Oscillator | 14.31 | 2.73 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply, and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture, as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and sales of construction materials.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.